|
US4200750A
(en)
|
1977-01-07 |
1980-04-29 |
Westwood Pharmaceuticals Inc. |
4-Substituted imidazo [1,2-a]quinoxalines
|
|
US6069143A
(en)
|
1994-12-20 |
2000-05-30 |
Smithkline Beecham Corporation |
Fibrinogen receptor antagonists
|
|
CA2472713C
(en)
|
2002-01-18 |
2011-07-19 |
Merck & Co., Inc. |
N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
|
|
US7479504B2
(en)
|
2002-01-18 |
2009-01-20 |
Merck & Co., Inc. |
Edg receptor agonists
|
|
AU2003216054B2
(en)
|
2002-01-18 |
2007-01-04 |
Merck & Co., Inc. |
Selective S1P1/Edg1 receptor agonists
|
|
AU2003217764A1
(en)
|
2002-03-01 |
2003-09-16 |
Merck & Co., Inc. |
Aminoalkylphosphonates and related compounds as edg receptor agonists
|
|
WO2003105771A2
(en)
|
2002-06-17 |
2003-12-24 |
Merck & Co., Inc. |
1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
|
|
CN1788008A
(zh)
*
|
2003-05-15 |
2006-06-14 |
麦克公司 |
作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
|
|
ES2467160T3
(es)
|
2003-05-19 |
2014-06-12 |
Irm Llc |
Compuestos y composiciones inmunosupresores
|
|
AU2004277947A1
(en)
*
|
2003-10-01 |
2005-04-14 |
Merck & Co., Inc. |
3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
|
|
EP1697333A4
(en)
|
2003-12-17 |
2009-07-08 |
Merck & Co Inc |
(3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
|
|
TW200538433A
(en)
|
2004-02-24 |
2005-12-01 |
Irm Llc |
Immunosuppressant compounds and compositiions
|
|
US7659294B2
(en)
|
2004-10-22 |
2010-02-09 |
Merck & Co., Inc. |
2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
|
|
DE602006003642D1
(en)
|
2005-03-23 |
2008-12-24 |
Actelion Pharmaceuticals Ltd |
Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
|
|
TW200642683A
(en)
|
2005-04-22 |
2006-12-16 |
Sankyo Co |
Heterocyclic compound
|
|
BRPI0612028A2
(pt)
|
2005-06-08 |
2010-10-13 |
Novartis Ag |
oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
|
|
CN101291908A
(zh)
|
2005-08-23 |
2008-10-22 |
Irm责任有限公司 |
免疫抑制剂化合物和组合物
|
|
WO2007088450A2
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
|
TW200806633A
(en)
|
2006-03-21 |
2008-02-01 |
Epix Pharm Inc |
S1P receptor modulating compounds and use thereof
|
|
PT2003132E
(pt)
|
2006-04-03 |
2014-05-26 |
Astellas Pharma Inc |
Derivados de oxadiazole como agonistas dos s1p1
|
|
JP2009269819A
(ja)
|
2006-08-25 |
2009-11-19 |
Asahi Kasei Pharma Kk |
アミン化合物
|
|
HRP20130180T1
(hr)
|
2006-09-08 |
2013-03-31 |
Actelion Pharmaceuticals Ltd. |
Derivati piridin-3-ila kao sredstva imunomodulacije
|
|
GB0625648D0
(en)
|
2006-12-21 |
2007-01-31 |
Glaxo Group Ltd |
Compounds
|
|
AU2008227979B2
(en)
|
2007-03-16 |
2014-02-06 |
Actelion Pharmaceuticals Ltd |
Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
|
|
CA2696863C
(en)
|
2007-10-04 |
2016-10-18 |
Anna Quattropani |
Oxadiazole derivatives
|
|
JP5517944B2
(ja)
|
2007-11-01 |
2014-06-11 |
アクテリオン ファーマシューティカルズ リミテッド |
新規なピリミジン誘導体
|
|
GB0725105D0
(en)
*
|
2007-12-21 |
2008-01-30 |
Glaxo Group Ltd |
Compounds
|
|
US20090298894A1
(en)
*
|
2008-04-21 |
2009-12-03 |
Asahi Kasei Pharma Corporation |
Amino acid compounds
|
|
CA2743397C
(en)
*
|
2008-12-18 |
2017-02-28 |
Mathilde Muzerelle |
Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
|
|
EP2202232A1
(en)
*
|
2008-12-26 |
2010-06-30 |
Laboratorios Almirall, S.A. |
1,2,4-oxadiazole derivatives and their therapeutic use
|
|
EP2210890A1
(en)
*
|
2009-01-19 |
2010-07-28 |
Almirall, S.A. |
Oxadiazole derivatives as S1P1 receptor agonists
|
|
JP2012515789A
(ja)
*
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
|
|
WO2010085582A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
EP2382212B1
(en)
*
|
2009-01-23 |
2014-07-16 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
US8399451B2
(en)
*
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
MX336881B
(es)
|
2009-10-29 |
2016-02-04 |
Bristol Myers Squibb Co |
Compuestos heterociclicos triciclicos.
|
|
US8835470B2
(en)
|
2010-04-23 |
2014-09-16 |
Bristol-Myers Squibb Company |
Mandelamide heterocyclic compounds
|
|
WO2012012477A1
(en)
|
2010-07-20 |
2012-01-26 |
Bristol-Myers Squibb Company |
Substituted 3-phenyl-1,2,4-oxadiazole compounds
|
|
EP2619190B1
(en)
|
2010-09-24 |
2015-08-12 |
Bristol-Myers Squibb Company |
Substituted oxadiazole compounds and their use as s1p1 agonists
|